Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".

NCT ID: NCT02489331 Phase: Status: COMPLETED Enrollment: 193 Completion: 2020-11-10

Conditions

Dyslipidemias

Summary

Post marketing surveillance of safety and efficacy for Cholib in Korean patients under the "New Drug Re-examination"

Primary Outcome

Incidence of adverse event after Cholib administration in general medical practice

Source

ClinicalTrials.gov